These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19110745)

  • 41. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
    Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
    Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Novel biologics in treatment of psoriatic arthritis].
    ZHOU J; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):404-8. PubMed ID: 19693980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etanercept.
    Ducharme E; Weinberg JM
    Expert Opin Biol Ther; 2008 Apr; 8(4):491-502. PubMed ID: 18352852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
    Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
    BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
    Kluger N; Girard C; Guillot B; Bessis D
    Acta Derm Venereol; 2009; 89(3):332-4. PubMed ID: 19479148
    [No Abstract]   [Full Text] [Related]  

  • 52. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA; Strober BE
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
    Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
    Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
    [No Abstract]   [Full Text] [Related]  

  • 55. Psoriatic arthritis: a guide for dermatology nurses.
    Gottlieb AB
    Dermatol Nurs; 2003 Apr; 15(2):107-10, 113-8; quiz 119. PubMed ID: 12751345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TNF-alpha inhibitors in dermatology.
    Cordoro KM; Feldman SR
    Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient profiles in psoriatic disease: a case-based approach.
    Wiatrowski M; Furfaro N
    Dermatol Nurs; 2007 Oct; Suppl():5-19; quiz 20-1. PubMed ID: 18341241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin.
    Braun J; Sieper J
    BioDrugs; 2003; 17(3):187-99. PubMed ID: 12749755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N; Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.